Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer.

[1]  W. Rom,et al.  Selective p38 activation in human non-small cell lung cancer. , 2002, American journal of respiratory cell and molecular biology.

[2]  J. McCubrey,et al.  The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia , 2002, Leukemia.

[3]  A. Marotta,et al.  Dysregulation of phosphatidylinositol 3‐kinase and downstream effectors in human breast cancer , 2002, International journal of cancer.

[4]  G. Woude,et al.  Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. McPherson,et al.  The role of mitogen-activated protein (MAP) kinase in breast cancer , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[6]  F. Hantash,et al.  Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells. , 2001, Cancer research.

[7]  J. Baselga,et al.  Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. , 2001, Cancer research.

[8]  T. Chambers,et al.  Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. , 2001, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[9]  K. Gall-Trošelj,et al.  Recent advances in molecular genetics of breast cancer , 2001, Journal of Molecular Medicine.

[10]  V. Keshamouni,et al.  Temporal and quantitative regulation of mitogen-activated protein kinase (MAPK) modulates cell motility and invasion , 2001, Oncogene.

[11]  A. Duhaime,et al.  Role of MAP kinase pathways in primitive neuroectodermal tumors. , 2001, Anticancer research.

[12]  M. Kazanietz,et al.  Constitutive ERK1/2 Activation in Esophagogastric Rib Bone Marrow Micrometastatic Cells Is MEK-independent* , 2001, The Journal of Biological Chemistry.

[13]  J. Uney,et al.  Inhibition of JNK by Overexpression of the JNK Binding Domain of JIP-1 Prevents Apoptosis in Sympathetic Neurons* , 2001, The Journal of Biological Chemistry.

[14]  L. Wang,et al.  Inhibition of mitogen-activated protein kinase kinase selectively inhibits cell proliferation in human breast cancer cells displaying enhanced insulin-like growth factor I-mediated mitogen-activated protein kinase activation. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[15]  I. Ellis,et al.  Biological and clinical associations of c‐jun activation in human breast cancer , 2000, International journal of cancer.

[16]  L. Luttrell,et al.  Activation of extracellular signal-regulated kinase in human prostate cancer. , 1999, Journal of Urology.

[17]  Roger J. Davis,et al.  The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins , 1999, Molecular and Cellular Biology.

[18]  A. Whitmarsh,et al.  Signal Transduction by MAP Kinases: Regulation by Phosphorylation-Dependent Switches , 1999, Science's STKE.

[19]  W. Imagawa,et al.  Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF. , 1999, Carcinogenesis.

[20]  J. Hahn,et al.  Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. , 1999, Blood.

[21]  H. Frierson,et al.  Activation of mitogen-activated protein kinase associated with prostate cancer progression. , 1999, Cancer research.

[22]  G. Johnson,et al.  The TAO of MEKK. , 1998, Frontiers in bioscience : a journal and virtual library.

[23]  S. Vandenberg,et al.  In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. , 1998, The American journal of pathology.

[24]  Y. Ip,et al.  Signal transduction by the c-Jun N-terminal kinase (JNK)--from inflammation to development. , 1998, Current opinion in cell biology.

[25]  N. Hayashi,et al.  Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma , 1998, Hepatology.

[26]  G. Johnson.  Signal transduction abnormalities in cancer mitogen-activated protein kinase regulation is altered in breast cancer. , 1997, The Journal of clinical investigation.

[27]  G. Nuovo,et al.  Hyperexpression of mitogen-activated protein kinase in human breast cancer. , 1997, The Journal of clinical investigation.

[28]  C. Malbon,et al.  jun N-terminal Kinase Mediates Activation of Skeletal Muscle Glycogen Synthase by Insulin in Vivo* , 1996, The Journal of Biological Chemistry.

[29]  M. Kawaichi,et al.  Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. , 1995, Cancer research.

[30]  C. Malbon,et al.  Steady-state levels of G-proteins and beta-adrenergic receptors in rat fat cells. Permissive effects of thyroid hormones. , 1988, The Journal of biological chemistry.

[31]  J. Shimazaki,et al.  Overexpression of mitogen-activated protein kinase superfamily proteins unrelated to Ras and AF-1 of estrogen receptor alpha mutation in advanced stage human breast cancer. , 2000, Pathology, research and practice.